Elevation Oncology Inc. (NASDAQ: ELEV)
$3.00
-0.0200 ( -0.66% ) 843.2K
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Market Data
Open
$3.00
Previous close
$3.02
Volume
843.2K
Market cap
$163.64M
Day range
$2.96 - $3.27
52 week range
$0.36 - $5.83
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 19, 2023 |
8-k | 8K-related | 14 | Nov 02, 2023 |
10-q | Quarterly Reports | 75 | Nov 02, 2023 |
8-k | 8K-related | 13 | Sep 22, 2023 |
4 | Insider transactions | 1 | Sep 19, 2023 |
4 | Insider transactions | 1 | Sep 05, 2023 |
8-k | 8K-related | 13 | Aug 16, 2023 |
8-k | 8K-related | 16 | Aug 03, 2023 |
10-q | Quarterly Reports | 75 | Aug 03, 2023 |
4 | Insider transactions | 1 | Jul 14, 2023 |